Unity Biotechnology (NASDAQ: UBX)
$1.50
(-0.7%)
-$0.01
Price as of April 19, 2024, 4:00 p.m. ET
Unity Biotechnology Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Unity Biotechnology Company Info
Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.
News & Analysis
Featured Article
Here's Why Unity Biotechnology Is Getting Crushed Today
The development-stage biopharma announced disappointing results from a clinical trial.
Maxx Chatsko | Aug 17, 2020
Featured Article
Unity Biotech: Buy at the Low?
Shares have been mired in a nearly continuous slide for the last year. Is Wall Street's pessimism misplaced?
Maxx Chatsko | Aug 22, 2019
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.